Reinigung von Rohren, Pipelines und Klimaanlagen mit COLD PowAir Rohr-Roboter - CPR100 - erstmals der Öffentlichkeit vorgestellt
Salzburg (ots) - Am 18. Oktober 2017 wurde in Bratislava der COLD PowAir Rohr-Roboter - CPR100 von Egger PowAir ...
München (ots) - Ab sofort verstärken Christiane Ritter, Tim Jungblut und Sebastian Schütze das Team von ...
München (ots) - Deutschlands bekannteste Auswanderer-Familie ist zurück - Neue Projekte und große ...
Princeton, New Jersey (ots/PRNewswire) -
New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.
Data will be presented on BARACLUDE(R) (entecavir) in patients with chronic hepatitis B, and on two compounds in early clinical development for the treatment of hepatitis C -- BMS-650032, an NS3 inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The presentation of data on BMS-650032 will mark the first public disclosure of information about this investigational compound. Data will also be presented on the investigational compound brivanib, the first selective dual inhibitor of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) signaling, which is in Phase 3 development for the treatment of hepatocellular carcinoma.
"The data on Bristol-Myers Squibb compounds that will be presented at AASLD demonstrate the breadth of our research and development portfolio and support the company's goal of developing innovative medicines for patients with various diseases of the liver," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "Our established expertise in viral hepatitis and oncology uniquely position Bristol-Myers Squibb to be at the forefront of delivering innovation in the treatment of multiple types and stages of liver disease. We are proud to be releasing new data on our significant portfolio of assets."
BARACLUDE, BMS-650032 and brivanib were discovered by Bristol-Myers Squibb Research and Development. BMS-650032 is Bristol-Myers Squibb's second small molecule under development for the treatment of hepatitis C, joining BMS-790052, a first-in-class investigational NS5A inhibitor of the hepatitis C virus.
PEG-Interferon lambda was discovered by ZymoGenetics, Inc. Bristol-Myers Squibb and ZymoGenetics announced a global collaboration for PEG-Interferon lambda and its related development program earlier this year.
The times, titles and lead authors of the data presentations are as follows:
Date/Time Presentation Title Lead Author
--------- ------------------ -----------
October 31, Efficacy and Safety of Y. Liaw
2:00 - 8:00 Entecavir versus Chang Gung
p.m. EDT Adefovir in Chronic Memorial Hospital,
Hepatitis B Patients Chang Gung
with Evidence of University
Hepatic College of Medicine
Decompensation Taipei, Taiwan
November 3, Safety, Tolerability, C. Pasquinelli
12:00 - 12:15 Pharmacokinetics and Bristol-Myers Squibb
p.m. EST Antiviral Activity
following Single- and
BMS-650032, a Novel
HCV NS3 Inhibitor, in
Subjects with Chronic
Genotype 1 HCV
November 3, Genotypic and F. McPhee
8:00 a.m. - Phenotypic Analysis Bristol-Myers Squibb
1:00 p.m. EST of Samples from
BMS-650032 in a
Single Ascending Dose
Study (Abstract #1607)
November 3, A Phase 1b A.J. Muir
8:00 a.m. - Dose-Ranging Study of Duke University
1:00 p.m. EST 4 Weeks of School of Medicine
PEG-Interferon (IFN) Durham, North Carolina
in Combination with
Ribavirin (RBV) in
Patients with Chronic
Genotype 1 Hepatitis
C Virus (HCV)
November 3, Time-to-Progression R. Finn
8:00 a.m. - Analysis of UCLA Los Angeles, CA
1:00 p.m. EST Second-line Treatment
with Brivanib in
November 3, Cell-dependent J. Park
8:00 a.m. - Response of National Cancer Center
1:00 p.m. EST BMS-582664 (Brivanib) Goyang, South Korea
Carcinoma Cells: Gene
Study (Abstract #1668)
Discovered at Bristol-Myers Squibb, BARACLUDE(R) is a nucleoside analogue indicated for use in adults with chronic hepatitis B infection with compensated liver disease, evidence of active viral replication, and either evidence of persistent elevations of the blood levels of aminotransferases - a marker for liver disease - or active liver disease as determined by biopsy. BARACLUDE (entecavir) has been approved in more than 86 countries and regions around the world.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.
BARACLUDE(R) (entecavir) is a registered trademark of Bristol-Myers Squibb Company.
ots Originaltext: Bristol-Myers Squibb GmbH & Co.KG aA
Im Internet recherchierbar: http://www.presseportal.ch